IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
139 hedge funds and large institutions have $1.58B invested in IVERIC bio, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 71 increasing their positions, 24 reducing their positions, and 20 closing their positions.
196% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 24
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
13% more capital invested
Capital invested by funds: $1.4B → $1.58B (+$179M)
8% more funds holding
Funds holding: 129 → 139 (+10)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
18% less call options, than puts
Call options by funds: $7.62M | Put options by funds: $9.33M
Top Buyers
Top Sellers
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$72.3M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$32.6M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$6.08M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$5.77M |
| 5 |
CCM
Cupps Capital Management
Chicago,
Illinois
|
-$5.47M |
ISEE Hedge Fund Activity: Q2 2015 in Review
139 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2015, worth a combined $1.58B — up 13% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ISEE positions and 20 closed out — a net gain of 10 holders — while 71 added to existing stakes and 24 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $30.4M. The largest seller was Clarus Ventures, exiting entirely with an estimated $72.3M sold.
- 139 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2015, up from 129 in Q1 2015.
- Funds reported $1.58B of IVERIC bio, Inc. Common Stock stock for Q2 2015, up 13% quarter-over-quarter.
- 30 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2015 and 20 closed out, a net change of +10 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q2 2015 was T. Rowe Price Associates, an estimated $30.4M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q2 2015 was Clarus Ventures, an estimated $72.3M sold.
Based on aggregated 13F filings for Q2 2015.